| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 45.17 | -0.53 (-1.16%) | 30.25 - 47.45 | 2.2 million (Below Avg) |
Market data as of 4:04PM 05/23/13. Quotes are delayed by at least 15 min.
| Open | 45.41 |
|---|---|
| Previous Close | 45.70 |
| Day's Range | 44.97 - 45.62 |
| Market Cap | 12.8B |
| Avg Volume (10 Day) | 2.9M |
| Price/Earnings (Trailing 12 Mo.) | 18.2x |
| Earnings Per Share (Trailing 12 Mo.) | 2.51 |
| Dividend Yield | 0.25 (2.21%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Pass |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Pass |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Pass |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
One Year Data from St. Jude Medical Study Demonstrates Safe, Rapid and Sustained Blood Pressure Reduction with EnligHTN Renal Denervation Technology
Business Wire - Thursday 05/23/2013 4:15 AM ET
St. Jude Medical EnligHTNment Study Highlighted at EuroPCR During Trials That May Change Clinical Practice Session
Business Wire - Tuesday 05/21/2013 9:52 AM ET
St. Jude Medical to Present at the 38th Annual Deutsche Bank Health Care Conference
Business Wire - Tuesday 05/21/2013 8:00 AM ET
St. Jude Medical Announces European Approval of 3-D Vessel Reconstruction Technology to Aid Physicians in Stent Placement
Business Wire - Thursday 05/16/2013 8:01 AM ET
St. Jude Medical Announces First Patient Enrollment in EnligHTN III Renal Denervation Study of Next-Generation EnligHTN System
Business Wire - Tuesday 05/14/2013 8:00 AM ET
St. Jude Medical Announces Results from Independent Analysis of Optim-Insulated Defibrillation Leads in Late-Breaking Clinical Trial Session at Heart Rhythm 2013
Business Wire - Thursday 05/09/2013 1:55 PM ET
St. Jude Medical Announces CE Mark Approval of Next-Generation Ellipse and SJM Assura High Voltage Devices
Business Wire - Wednesday 05/08/2013 8:00 AM ET
St. Jude Medical to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Business Wire - Friday 05/03/2013 8:54 AM ET
| STJ | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -3.29% | |
| Net Income Growth (1yr) | 51.42% | |
| Total Debt/Equity | 0.90 | |
| LT Debt/Equity | 0.76 | |
| Earnings Yield | 5.49% | |
| Price/Sales | 2.38 |
| Company | Last | Change |
|---|---|---|
| Zimmer Holdings Inc | 79.95 | +0.11% |
| Boston Scientific Corp | 9.16 | +0.33% |
| Smith & Nephew PLC | 59.39 | +0.22% |
| Varian Medical Systems Inc | 67.89 | -0.79% |
| Edwards Lifesciences Corp | 65.72 | +2.21% |
Data is delayed by at least 15 min.